The results of the KEYNOTE 024 [87], KEYNOTE 189 [88] and KEYNOTE 407 [89] trials demonstrate favourable long-term outcome effects with ICI monotherapy in patients with a tumour proportion score for programmed death-ligand 1 (PD-L1) of ≥50%, as well as with an ICI in combination with chemotherapy. Here, CD274 is linked to neoplasm.